Navigating New Waters for Advanced or Recurrent Endometrial Cancer

Patient prognosis for endometrial cancer (EC) is highly benefited by molecular profiling, and national and international guidelines robustly recommend its integration into practice. Characterization of DNA mismatch repair (MMR) status identifies clinically significant molecular subtypes. This information assists clinicians in creating treatment plans tailored to specific tumor phenotypes and individual needs, including those patients with advanced and recurrent EC. Despite ringing endorsements and clear clinical applications, however, molecular profiling remains underutilized due to logistical challenges and a lack of clinician confidence. It is imperative that clinicians, in collaboration with the multidisciplinary team (MDT), become knowledgeable about this exciting technique and utilize it to enhance treatment decisions for patients.

In this CE Concepts enduring webcast, expert faculty will guide learners through integration of appropriate, guideline-directed molecular profiling strategies in the EC risk assessment and treatment decision process. Faculty will also assess the latest efficacy and safety data for the treatment of EC with learners and develop guideline-concordant and patient-specific therapeutic plans for patients with newly diagnosed advanced or recurrent EC that incorporate MDT collaboration strategies.

At the conclusion of this activity, learners will be able to better:

• Integrate appropriate, guideline-directed molecular profiling strategies in the EC risk assessment and treatment decision process
• Assess the latest efficacy and safety data for the treatment of EC factoring in updates to guidelines
• Develop a guideline-concordant and patient-specific therapeutic plan for patients with newly diagnosed advanced or recurrent EC utilizing MDT collaboration strategies

Supported by an educational grant from AstraZeneca Pharmaceuticals and Merck & Co., Inc., Rahway, NJ, USA.

Gynecologic oncologists, pathologists, gynecologists, physician associates (PAs), nurse practitioners (NPs), nurses, and other HCPs part of the MDT

Dr. Penson reports the following financial relationships:

Advisory Board: Aadi Bioscience; AstraZeneca; GSK; ImmunoGen, Inc.; Merck & Co., Inc.; Mersana Therapeutics, Inc.; Novacure; Roche; Sutro Biopharma, Inc.; and Vascular Biogenics

Consultant: Serves on DSMBs for AstraZeneca; EQRx; and Roche

Research Support: Institutional research funding (as PI) for Array BioPharma Inc.; AstraZeneca; Eisai Inc.; Genentech, Inc.; and Vascular Biogenics

Other financial or material support: Royalties: BMJ Publishing Group Ltd; Elsevier; UpToDate, Inc.; Wolters Kluwer Health and Wiley-Blackwell. Payment for educational events: Research to Practice; ExpertConnect; and ReachMD

Ms. Anastasia reports no financial relationships to disclose.

Dr. Devins reports no financial relationships to disclose.

The following individuals have no financial relationships to disclose: 

Alaa Bawaneh, MD, PhD (Peer Reviewer)
Elizabeth Naber, MSN, RN, CCRN-K, CNRN, TCRN (Peer Reviewer)
Keshia Pitt, PhD (Planning Committee)
Katherine Lee, PharmD, MPH (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)